{"analyses":[{"ciLowerLimit":"0.14","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.47","groupDescription":"Log-rank test was stratified by randomization stratification factors.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.00001","paramType":"Hazard Ratio (HR)","paramValue":"0.26","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.0","upperLimit":"86.6","value":"78.0"},{"groupId":"OG001","lowerLimit":"26.2","upperLimit":"50.5","value":"38.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"},{"groupId":"OG001","value":"94"}],"units":"Participants"}],"description":"Event-free rate estimated at 12 months for cGFS per EAC, which is defined as the time from date of allogeneic hematopoietic cell transplantation (alloHCT) (ie, day 0) to date of death from any cause or first onset of moderate or severe chronic graft-versus-host disease (cGVHD) (graded per NIH consensus criteria), whichever was earliest, within 2 years after day 0. cGVHD was assessed and graded by EAC blinded to treatment assignment.\n\nEach participant in the study is followed for up to 730 days after transplant. Primary analysis was event driven (ie, when 56 participants had died or had moderate or severe cGVHD) and was not based on duration of follow-up. The analysis was conducted using all available data at the time that the 56th event occurred, and event-free rate at 12 months was estimated regardless of length of follow-up for individual participants. At the time of analysis, not all participants have reached 730 days of follow-up because they enrolled at different times.","dispersionType":"95% Confidence Interval","groups":[{"description":"Orca-T administered after myeloablative conditioning followed by single-agent tacrolimus","id":"OG000","title":"Orca-T"},{"description":"Unmanipulated allograft from peripheral blood of a matched donor after myeloablative conditioning followed by tacrolimus and methotrexate","id":"OG001","title":"Standard of Care"}],"paramType":"NUMBER","populationDescription":"ITT","reportingStatus":"POSTED","timeFrame":"Day 0 through 730 days after transplantation","title":"Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}